Overview

A Trial of TTA-121 on Autism Spectrum Disorder

Status:
Active, not recruiting

Trial end date:
2020-03-30

Target enrollment:

Participant gender:

Summary

To test efficacy and safety of a novel nasal spray of oxytocin on social deifies in autism spectrum disorder, and To compare effect sizes of different doses

Phase:

Phase 2

Details

Lead Sponsor:

Hamamatsu University

Collaborator:

Japan Agency for Medical Research and Development